Artery Therapeutics, Inc.
San Ramon, CA Doing business as Artery Therapeutics Inc.
- UEI
- JHVKQN55S7Y5
- CAGE
- 62AP0
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 10 Duberstein Dr, San Ramon, CA 94583, USA
- Website
- arterytx.com
- Founded
- 2004
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| CS6253 sequential subcutaneous pharmacokinetic study followed by phase 2A placebo-controlled trial with three fixed… | National Institute on Aging | $2,644,490 | |
| Manufacturing of ABCA1 agonist small molecule peptide CS6253 to support chronic toxicology studies in wistar rats and… | National Institute on Aging | $2,454,521 | |
| A randomized double-blind placebo controlled phase 1 SAD study in male and female healthy volunteers to assess safety,… | National Institute on Aging | $11,426,411 | |
| CS6253 development for the treatment of APOE4 driven dementia includingalzheimer's disease | National Institute on Aging | $2,855,667 |
About Artery Therapeutics, Inc.
Artery Therapeutics, Inc., a self-certified small disadvantaged business based in San Ramon, California, operates as a prime recipient of federal biomedical research grants from the National Institute on Aging, conducting clinical-stage drug development and manufacturing activities in support of neurodegenerative disease therapeutics.
Artery is a for-profit corporate entity with no federal contracting footprint; its entire federal engagement to date consists of four Project Grants and Cooperative Agreements from the National Institute on Aging (CFDA 93.866 — Aging Research program) totaling $19.4 million obligated since 2019. The vendor's customer concentration is singular: all four awards derive from a single federal agency (NIH/National Institute on Aging, 100% of awards). Two of the four awards face ultimate completion within the next twenty-four months, representing potential recompete opportunity.
Artery's federal work centers on CS6253, a second-generation ABCA1 transporter agonist peptide candidate for hereditary APOE4-associated dementia and mild cognitive impairment. The most recent award — a $2.64 million Cooperative Agreement dated February 15, 2026, completing March 15, 2028 — funds two sequential clinical research studies: a subcutaneous pharmacokinetic feasibility study followed by a Phase 2A mechanism and proof-of-concept trial enrolling 48 APOE4 carriers with mild cognitive impairment to evaluate safety, tolerability, pharmacokinetics, and biomarker effects. A $2.45 million Project Grant dated September 10, 2025, completing August 31, 2026, covers manufacturing of approximately 2.3 kilograms of Good Manufacturing Practices-compliant drug substance for chronic toxicology studies in rodents and primates, executed in partnership with Ambiopharm, Inc., a Contract Development and Manufacturing Organization. An earlier $2.45 million Project Grant from September 2021 (completed December 2024) supported Phase 1 clinical trial material and chemistry, manufacturing, and controls activities. A fourth award from June 2019 funded foundational work leading to Investigational New Drug regulatory submission.
Quick answers
What is Artery Therapeutics, Inc.'s UEI?
Artery Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is JHVKQN55S7Y5.
What is Artery Therapeutics, Inc.'s CAGE code?
Artery Therapeutics, Inc.'s CAGE code is 62AP0.
What is Artery Therapeutics, Inc.'s primary NAICS code?
Artery Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Artery Therapeutics, Inc. located?
Artery Therapeutics, Inc.'s physical address in SAM.gov is 10 Duberstein Dr, San Ramon, CA 94583, USA.
Is Artery Therapeutics, Inc. registered in SAM.gov?
Yes. Artery Therapeutics, Inc.'s SAM.gov registration is active through August 7, 2027.
What is Artery Therapeutics, Inc.'s most recent federal award?
Artery Therapeutics, Inc.'s most recent federal grant award is CS6253 sequential subcutaneous pharmacokinetic study followed by phase 2A placebo-controlled trial with three fixed… (UG3AG098023), from National Institute on Aging, on February 15, 2026.
On GovTribe
See Artery Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors